Why uniQure’s AMT-130 For Huntington’s Is Not "Too Good To Be True"
Despite impressive Phase I/II AMT-130 results, the FDA views current data as insufficient. Volumetric inclusion criteria may have raised concerns about potential bias. However, analysis indicates the thresholds were sufficiently inclusive, supporting the reported therapeutic effect.